Immunomodulatory agents changing the landscape of multiple myeloma treatment

Critical Reviews in Oncology/Hematology

Volumn 88, Issue SUPPL.1, 2013, Pages S1-

  Niesvizky, Ruben ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PLACEBO; POMALIDOMIDE; PREDNISONE; THALIDOMIDE;

ADD ON THERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; INCIDENCE; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE MYELOMA; NEUROTOXICITY; OVERALL SURVIVAL; PATHOGENESIS; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; REVIEW; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA;

EID: 84882624372     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.12.011     Document Type: Review

References (47)

1. Jemal A., Siegel R., Xu J., Ward E. Cancerstatistics, 2010. CA: A Cancer Journal for Clinicians 2010, 60:277-300.
2. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nature Reviews Cancer 2002, 2:927-937.
3. Pratt G., Goodyear O., Moss P. Immunodeficiency and immunotherapy in multiple myeloma. British Journal of Haematology 2013, 88:S14-S22.
4. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2013, 88:S23-S35.
5. Mitsiades C., Chen-Kiang S. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Critical Reviews in Oncology/Hematology 2013, 88:S36-S44.
6. Palumbo A., Anderson K. Multiple myeloma. New England Journal of Medicine 2011, 364:1046-1060.
7. Agarwal J.R., Matsui W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anti-Cancer Agents in Medicinal Chemistry 2010, 10:116-120.
8. Schütt P., Brandhorst D., Stellberg W., et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leukemia and Lymphoma 2006, 47:1570-1582.
9. Corral L.G., Haslett P.A.J., Muller G.W., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. Journal of Immunology 1999, 163:380-386.
10. Galustian C., Meyer B., Labarthe M.C., et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology, Immunotherapy 2009, 58:1033-1045.
11. Morgan G., Davies F. Role of thalidomide in the treatment of patients with multiple myeloma. Critical Reviews in Oncology/Hematology 2013, 88:S14-S22.
12. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine 1999, 341:1565-1571.
13. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:4082-4085.
14. Hideshima T., Chauhan D., Shima Y., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
15. Ludwig H., Beksac M., Bladé J., et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010, 15:6-25.
16. Glasmacher A., Hahn C., Hoffmann F., et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. British Journal of Haematology 2006, 132:584-593.
17. Wang M., Dimopoulos M.A., Chen C., et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008, 112:4445-4451.
18. Lokhorst H.M., Schmidt-Wolf I., Sonneveld P., et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008, 93:124-127.
19. Lokhorst H.M., van der Holt B., Zweegman S., et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115:1113-1120.
20. Hahn-Ast C., von Lilienfeld-Toal M., van Heteren P., et al. Improved progression-free and overall survival with thalidomide maintenance therapy after autologous stem cell transplantation in multiple myeloma: a meta-analysis of five randomized trials. Haematologica 2011, 95. [abstract 0884].
21. Mileshkin L., Prince H.M. The troublesome toxicity of peripheral neuropathy with thalidomide. Leukemia and Lymphoma 2006, 47:2276-2279.
22. Mohty B., El-Cheikh J., Yakoub-Agha I., et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010, 95:311-319.
23. Offidani M., Corvatta L., Polloni C., et al. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. Annals of Hematology 2011, 90:1449-1456.
24. ClinicalTrials.gov. MMVAR - Velcade: Study of Velcade for the treatment of myeloma patients after autologous transplantation. [accessed 11.1.11]. http://clinicaltrials.gov/ct2/show/NCT00256776.
25. Dimopoulos M., Terpos E., Niesvizky R. How lenalidomide is changing the treatment of patients with multiple myeloma. Critical Reviews in Oncology/Hematology 2013, 88:S23-S35.
26. Chanan-Khan A.A., Cheson B.D. Lenalidomide for the treatment of B-cell malignancies. Journal of Clinical Oncology 2008, 26:1544-1552.
27. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine 2007, 357:2123-2132.
28. Weber D., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine 2007, 357:2133-2142.
29. Stadtmauer E.A., Weber D.M., Niesvizky R., et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. European Journal of Haematology 2009, 82:426-432.
30. San Miguel J.F., Dimopoulos M.A., Stadtmauer E.A., et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma, Myeloma and Leukemia 2011, 11:38-43.
31. Harousseau J.L., Dimopoulos M.A., Wang M., et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010, 95:1738-1744.
32. Attal M., Lauwers-Cances V., Marit G., et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. New England Journal of Medicine 2012, 3661782-3661791.
33. Palumbo A., Hajek R., Delforge M., et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. New England Journal of Medicine 2012, 3661759-3661769.
34. Rajkumar S.V., Jacobus S., Callander N.S., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncology 2010, 11:29-37.
35. Zonder J.A., Crowley J., Hussein M.A., et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010, 116:5838-5841.
36. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. New England Journal of Medicine 2012, 366(19):1770-1781.
37. Lonial S., Baz R., Swern A.S., Weber D., Dimopoulos M.A. Neutropenia is a predictable and early event in affected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone. Blood 2009, 114. [abstract 2879].
38. Moreau P., Richardson P., Lonial S., et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: a randomized phase 2 study. Haematologica 2011, 96(Suppl. 2). [abstract 1007].
39. Niesvizky R., Jayabalan D.S., Christos P.J., et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008, 111:1101-1109.
40. Niesvizky R., Bensinger W., Martin T., et al. An update on the phase 1b/2 dose-escalation study of carfilzomib with lenalidomide and low-dose dexamethasone (CRd) in patients with relapsed or refractory multiple myeloma. Haematologica 2011, 96(Suppl. 2). [abstract 0295].
41. Richardson P.G., Weller E., Lonial S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
42. Richardson P., Mark T., Lacy M. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. Critical Reviews in Oncology/Hematology 2013, 88:S36-S44.
43. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
44. Lacy M.Q., Hayman S.R., Gertz M.A., et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010, 24:1934-1939.
45. Lacy M.Q., Allred J.B., Gertz M.A., et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. Blood 2011, 118:2970-2975.
46. Leleu X., Attal M., Arnulf B., et al. Phase 2 multicenter, randomized open label study of 2 modalities of pomalidomide plus low-dose dexamethasone (POMD) in patients with multiple myeloma (MM) refractory to both lenalidomide and bortezomib (double refractory). IFM 2009-02. Haematologica 2011, 96(Suppl. 1):148.
47. Richardson P.G., Siegel D., Baz R., et al. A phase 1/2 multicenter, randomized, open-label dose-escalation study to determine the maximum tolerated dose (MTD), safety and efficacy of pomalidomide (POM) alone or in combination with low-dose dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma (RRMM) who have received prior treatment (TX) that includes lenalidomide (LEN) and bortezomib (BORT). Haematologica 2011, 96(Suppl. 1):12.